| Recruiting | A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer Platinum-resistant Ovarian Cancer | Phase 1 | 2025-11-01 |
| Recruiting | A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute My Acute Myeloid Leukemia | Phase 2 | 2025-01-14 |
| Recruiting | A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer Advanced Breast Cancer | Phase 1 | 2024-10-25 |
| Recruiting | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer Breast Cancer | Phase 3 | 2024-09-27 |
| Active Not Recruiting | ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Metastatic Breast Cancer | Phase 2 | 2023-05-19 |
| Completed | A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Functi Hepatic Impairment | Phase 1 | 2023-03-13 |
| Recruiting | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participant Breast Cancer, Metastatic Breast Cancer | Phase 1 / Phase 2 | 2023-01-24 |
| Recruiting | Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer Breast Neoplasms, Brain Neoplasms, Neoplasms by Site | Phase 1 / Phase 2 | 2022-08-31 |
| Terminated | Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2021-03-19 |
| Completed | Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Breast Cancer | Phase 3 | 2019-05-10 |
| Completed | Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer Hormone Receptor Positive Malignant Neoplasm of Breast | Phase 1 | 2017-10-23 |
| Completed | Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Metastatic Breast Cancer | Phase 1 | 2016-04-01 |
| Completed | A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors Solid Tumors | Phase 1 | 2016-02-23 |
| Completed | Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) Myelofibrosis, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | 2016-02-10 |
| Terminated | SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myel Multiple Myeloma | Phase 1 / Phase 2 | 2016-01-01 |
| Terminated | SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remissi Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2015-02-01 |
| Completed | A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced ER+, HER2-Negative Breast Cancer | Phase 1 | 2015-01-01 |
| Completed | Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | 2014-09-01 |
| Completed | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multi Adult Brain Glioblastoma, Glioblastoma Multiforme | Phase 1 / Phase 2 | 2014-05-01 |